Nasrin Akter1, Sarker Hafiz Mahmud2, Saniad Ahmed Sakin3, Smita Roy4, A.K.M Mosharrof Hossain5, Forhat Mohal6, Md. Shamsul Islam7
1. Assistant Professor, Department of Pharmacology, North East Medical College, Sylhet.
2. Assistant Professor, Department of Pharmacology, Mainamoti Medical College, Comilla
3. Assistant Professor, Department of Pharmacology, Brahmanbaria Medical College, Brahmanbaria
4. Senior Lecturer, Department of Biochemistry, North East Medical College, Sylhet.
5. Professor, Department of Pharmacology, Sylhet M.A.G Osmani Medical College, Sylhet.
6. Professor, Department of Gynaecology, North East Medical College, Sylhet.
7. Assistant Register, Department of Medicine, Sylhet M.A.G Osmani Medical College, Sylhet.
Abstract
A prospective comparative study was conducted on 133 patients attending the Outpatient Department of Obstetrics and Gynaecology, Sylhet M.A.G Osmani Medical College Hospital and North East Medical College Hospital, Sylhet during the period from 1st July 2014 to 30th June 2015, complaining postmenopausal vasomotor symptoms and they were divided randomly into two groups, group A (n=63) treated with tibolone 2.5 mg daily and another group B (n=70) treated with venlafaxine 75 mg daily for 12 weeks. In each follow up visit severity of VMS (Vasomotor symptoms) rating was recorded by using 21 point in Greene Climacteric Scale (GCS). There was significant reduction in psychological score somatic score, vasomotor symptoms score and sexual symptoms score (p<0.001) at the end of the treatment period, compared to base line level but there was no significant difference between two treatment group before initiation of treatment, at 4. 8 and 12th week (p>0.05 each) of study period Decrease of psychological score was more pronounced in venlafaxine treated group at 4 week (p=0.019), at 8th week (p<0.001), and at 12th week (p<0.001) of treatment. Adverse effects reported in the present study were mild and no discontinuation was needed. Present study shows that, tibolone and venlafaxine are effective in treatment of postmenopausal VMS with acceptable safety profile.
Key Words: Postmenopausal Vasomotor Symptoms, Tibolone, Venlafaxine.